Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of atiprimod treatment in patients with low
to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable
local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing)
despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).